<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="9" family="GillSans,BoldItalic" color="#000000"/>
	<fontspec id="font6" size="7" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font7" size="10" family="Symbol" color="#000000"/>
	<fontspec id="font8" size="10" family="Giovanni-BookItalic,Italic" color="#000000"/>
	<fontspec id="font9" size="11" family="GillSans,Bold" color="#000000"/>
<text top="41" left="55" width="208" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title"><i>Current Controlled Trials in Cardiovascular Medicine</i></text>
<text top="41" left="263" width="27" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="0" tag_type="title"> 2005, </text>
<text top="41" left="291" width="5" height="10" font="font2" id="p1_t3" reading_order_no="2" segment_no="0" tag_type="title"><b>6</b></text>
<text top="41" left="296" width="13" height="10" font="font1" id="p1_t4" reading_order_no="3" segment_no="0" tag_type="title">:15</text>
<text top="41" left="373" width="181" height="10" font="font1" id="p1_t5" reading_order_no="4" segment_no="1" tag_type="text">http://cvm.controlled-trials.com/content/6/1/15</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t6" reading_order_no="114" segment_no="17" tag_type="text">Page 6 of 9</text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t7" reading_order_no="115" segment_no="18" tag_type="text"><i>(page number not for citation purposes)</i></text>
<text top="87" left="55" width="241" height="9" font="font4" id="p1_t8" reading_order_no="5" segment_no="2" tag_type="text">may be repeated if the first set of pullback images were</text>
<text top="98" left="55" width="125" height="9" font="font4" id="p1_t9" reading_order_no="6" segment_no="2" tag_type="text">judged suboptimal in quality.</text>
<text top="122" left="55" width="56" height="9" font="font5" id="p1_t10" reading_order_no="7" segment_no="5" tag_type="title"><i><b>IVUS Analysis</b></i></text>
<text top="134" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="8" segment_no="6" tag_type="text">The IVUS images will be sent to an independent core lab-</text>
<text top="145" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="9" segment_no="6" tag_type="text">oratory and interpreted by an experienced cardiologist</text>
<text top="157" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="10" segment_no="6" tag_type="text">blinded to treatment allocation. The methods for the</text>
<text top="169" left="55" width="241" height="9" font="font4" id="p1_t14" reading_order_no="11" segment_no="6" tag_type="text">analysis have been previously reported and va<a href="">lidated [49].</a></text>
<text top="181" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="12" segment_no="6" tag_type="text">Briefly, using the aorto-ostial anastomosis as a landmark,</text>
<text top="192" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="13" segment_no="6" tag_type="text">the most proximal 40 mm of vein graft will be analyzed.</text>
<text top="204" left="55" width="241" height="9" font="font4" id="p1_t17" reading_order_no="14" segment_no="6" tag_type="text">The video images will be digitized and measurements of</text>
<text top="216" left="55" width="241" height="9" font="font4" id="p1_t18" reading_order_no="15" segment_no="6" tag_type="text">lumen, intimal hyperplasia, and external elastic lamina</text>
<text top="228" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="16" segment_no="6" tag_type="text">areas will be available for each digitized cross section. Inti-</text>
<text top="239" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="17" segment_no="6" tag_type="text">mal hyperplasia volumes will be computed by multiply-</text>
<text top="251" left="55" width="241" height="9" font="font4" id="p1_t21" reading_order_no="18" segment_no="6" tag_type="text">ing the corresponding areas of each of the cross-sections</text>
<text top="263" left="55" width="241" height="9" font="font4" id="p1_t22" reading_order_no="19" segment_no="6" tag_type="text">by the distance between slices and by adding the products.</text>
<text top="275" left="55" width="241" height="9" font="font4" id="p1_t23" reading_order_no="20" segment_no="6" tag_type="text">For the purpose of this study, the mean plaque area per</text>
<text top="286" left="55" width="241" height="9" font="font4" id="p1_t24" reading_order_no="21" segment_no="6" tag_type="text">patient for the 40 mm-analyzed segment will be used for</text>
<text top="298" left="55" width="165" height="9" font="font4" id="p1_t25" reading_order_no="22" segment_no="6" tag_type="text">comparison between treatment groups.</text>
<text top="322" left="55" width="50" height="9" font="font5" id="p1_t26" reading_order_no="23" segment_no="9" tag_type="title"><i><b>Sample Size</b></i></text>
<text top="333" left="55" width="241" height="9" font="font4" id="p1_t27" reading_order_no="24" segment_no="10" tag_type="text">The trial will be powered to test the hypothesis that clopi-</text>
<text top="345" left="55" width="241" height="9" font="font4" id="p1_t28" reading_order_no="25" segment_no="10" tag_type="text">dogrel and aspirin should reduce vein graft intimal hyper-</text>
<text top="357" left="55" width="241" height="9" font="font4" id="p1_t29" reading_order_no="26" segment_no="10" tag_type="text">plasia by 20% compared to aspirin alone at one year</text>
<text top="369" left="55" width="241" height="9" font="font4" id="p1_t30" reading_order_no="27" segment_no="10" tag_type="text">following bypass surgery. According to Hozumi et al., at</text>
<text top="380" left="55" width="241" height="9" font="font4" id="p1_t31" reading_order_no="28" segment_no="10" tag_type="text">one year, the mean intimal area of angiographically nor-</text>
<text top="392" left="55" width="165" height="9" font="font4" id="p1_t32" reading_order_no="29" segment_no="10" tag_type="text">mal saphenous vein grafts is 5.26 mm</text>
<text top="392" left="220" width="4" height="6" font="font6" id="p1_t33" reading_order_no="30" segment_no="10" tag_type="text">2</text>
<text top="392" left="223" width="73" height="9" font="font4" id="p1_t34" reading_order_no="31" segment_no="10" tag_type="text">, with a standard</text>
<text top="404" left="55" width="102" height="9" font="font4" id="p1_t35" reading_order_no="32" segment_no="10" tag_type="text">deviation of 1.38 mm</text>
<text top="403" left="157" width="6" height="6" font="font6" id="p1_t36" reading_order_no="33" segment_no="10" tag_type="text">2 </text>
<text top="404" left="164" width="132" height="9" font="font4" id="p1_t37" reading_order_no="34" segment_no="10" tag_type="text"><a href="">[50]</a>. Intravascular ultrasound</text>
<text top="416" left="55" width="241" height="9" font="font4" id="p1_t38" reading_order_no="35" segment_no="10" tag_type="text">imaging will be performed at follow-up in one vein graft</text>
<text top="427" left="55" width="241" height="9" font="font4" id="p1_t39" reading_order_no="36" segment_no="10" tag_type="text">per patient. In order to account for potential angiographic</text>
<text top="439" left="55" width="241" height="9" font="font4" id="p1_t40" reading_order_no="37" segment_no="10" tag_type="text">refusals and study withdrawals, approximately 100</text>
<text top="451" left="55" width="241" height="9" font="font4" id="p1_t41" reading_order_no="38" segment_no="10" tag_type="text">patients in total will be required to test the null hypothesis</text>
<text top="463" left="55" width="34" height="9" font="font4" id="p1_t42" reading_order_no="39" segment_no="10" tag_type="text">with an </text>
<text top="460" left="90" width="6" height="13" font="font7" id="p1_t43" reading_order_no="40" segment_no="10" tag_type="text">Î±</text>
<text top="463" left="96" width="147" height="9" font="font4" id="p1_t44" reading_order_no="41" segment_no="10" tag_type="text"> value of 0.05 and a power of 0.90.</text>
<text top="486" left="55" width="163" height="9" font="font5" id="p1_t45" reading_order_no="42" segment_no="11" tag_type="title"><i><b>Data Collection and Safety Monitoring</b></i></text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t46" reading_order_no="43" segment_no="12" tag_type="text">Intimal area will be recorded at the time of IVUS one year</text>
<text top="510" left="55" width="241" height="9" font="font4" id="p1_t47" reading_order_no="44" segment_no="12" tag_type="text">after CABG. Vein graft patency and stenosis will be</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t48" reading_order_no="45" segment_no="12" tag_type="text">assessed by angiography. The incidence of major adverse</text>
<text top="533" left="55" width="241" height="9" font="font4" id="p1_t49" reading_order_no="46" segment_no="12" tag_type="text">coronary events and bleeding complications will be docu-</text>
<text top="545" left="55" width="241" height="9" font="font4" id="p1_t50" reading_order_no="47" segment_no="12" tag_type="text">mented during postoperative clinic visits at one month,</text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t51" reading_order_no="48" segment_no="12" tag_type="text">six months and twelve months after surgery. Telephone</text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t52" reading_order_no="49" segment_no="12" tag_type="text">home assessments every three months will also be used to</text>
<text top="580" left="55" width="241" height="9" font="font4" id="p1_t53" reading_order_no="50" segment_no="12" tag_type="text">document events. All serious adverse events will be</text>
<text top="592" left="55" width="241" height="9" font="font4" id="p1_t54" reading_order_no="51" segment_no="12" tag_type="text">reported to the ethics committee. The development of</text>
<text top="604" left="55" width="241" height="9" font="font4" id="p1_t55" reading_order_no="52" segment_no="12" tag_type="text">serious adverse events that might be attributable to clopi-</text>
<text top="615" left="55" width="222" height="9" font="font4" id="p1_t56" reading_order_no="53" segment_no="12" tag_type="text">dogrel will lead to the termination of the study drug.</text>
<text top="639" left="55" width="25" height="9" font="font5" id="p1_t57" reading_order_no="54" segment_no="14" tag_type="title"><i><b>Ethics</b></i></text>
<text top="651" left="55" width="241" height="9" font="font4" id="p1_t58" reading_order_no="55" segment_no="15" tag_type="text">The study will adhere to the highest research ethics stand-</text>
<text top="662" left="55" width="241" height="9" font="font4" id="p1_t59" reading_order_no="56" segment_no="15" tag_type="text">ards of the OHI. This protocol follows the CONSORT</text>
<text top="674" left="55" width="241" height="9" font="font4" id="p1_t60" reading_order_no="57" segment_no="15" tag_type="text">guidelines <a href="">[51] a</a>nd was approved on July 19, 2005 by the</text>
<text top="686" left="55" width="241" height="9" font="font4" id="p1_t61" reading_order_no="58" segment_no="15" tag_type="text">University of Ottawa Heart Institute Human Research Eth-</text>
<text top="698" left="55" width="41" height="9" font="font4" id="p1_t62" reading_order_no="59" segment_no="15" tag_type="text">ics Board.</text>
<text top="87" left="313" width="77" height="9" font="font5" id="p1_t63" reading_order_no="60" segment_no="3" tag_type="title"><i><b>Statistical Analysis</b></i></text>
<text top="98" left="313" width="241" height="9" font="font4" id="p1_t64" reading_order_no="61" segment_no="4" tag_type="text">Vein graft intimal area, the primary outcome of the study,</text>
<text top="110" left="313" width="241" height="9" font="font4" id="p1_t65" reading_order_no="62" segment_no="4" tag_type="text">will be compared between the two randomization groups</text>
<text top="122" left="313" width="241" height="9" font="font4" id="p1_t66" reading_order_no="63" segment_no="4" tag_type="text">using two-sided Student's t tests. Vein graft patency will be</text>
<text top="134" left="313" width="241" height="9" font="font4" id="p1_t67" reading_order_no="64" segment_no="4" tag_type="text">compared using a Fisher's exact test. With respect to the</text>
<text top="145" left="313" width="241" height="9" font="font4" id="p1_t68" reading_order_no="65" segment_no="4" tag_type="text">secondary outcomes, continuous data will be compared</text>
<text top="157" left="313" width="241" height="9" font="font4" id="p1_t69" reading_order_no="66" segment_no="4" tag_type="text">between the two groups using two-sided Student's t tests,</text>
<text top="169" left="313" width="241" height="9" font="font4" id="p1_t70" reading_order_no="67" segment_no="4" tag_type="text">two-sample Wilcoxon rank-sum tests, or ANOVA as</text>
<text top="181" left="313" width="241" height="9" font="font4" id="p1_t71" reading_order_no="68" segment_no="4" tag_type="text">appropriate, and a Fisher's exact test will be used for cate-</text>
<text top="192" left="313" width="241" height="9" font="font4" id="p1_t72" reading_order_no="69" segment_no="4" tag_type="text">gorical data. In order to assess possible interactions</text>
<text top="204" left="313" width="241" height="9" font="font4" id="p1_t73" reading_order_no="70" segment_no="4" tag_type="text">between patient characteristics (such as diabetes) and</text>
<text top="216" left="313" width="241" height="9" font="font4" id="p1_t74" reading_order_no="71" segment_no="4" tag_type="text">treatment outcomes, an exploratory analysis using multi-</text>
<text top="228" left="313" width="241" height="9" font="font4" id="p1_t75" reading_order_no="72" segment_no="4" tag_type="text">variate linear regression will be performed. In the improb-</text>
<text top="239" left="313" width="241" height="9" font="font4" id="p1_t76" reading_order_no="73" segment_no="4" tag_type="text">able event that all vein grafts are occluded and IVUS</text>
<text top="251" left="313" width="241" height="9" font="font4" id="p1_t77" reading_order_no="74" segment_no="4" tag_type="text">cannot be performed in a particular patient undergoing</text>
<text top="263" left="313" width="241" height="9" font="font4" id="p1_t78" reading_order_no="75" segment_no="4" tag_type="text">the one-year study, a value of five times the mean intimal</text>
<text top="275" left="313" width="59" height="9" font="font4" id="p1_t79" reading_order_no="76" segment_no="4" tag_type="text">area (decided </text>
<text top="275" left="372" width="29" height="9" font="font8" id="p1_t80" reading_order_no="77" segment_no="4" tag_type="text"><i>a priori</i></text>
<text top="275" left="401" width="141" height="9" font="font4" id="p1_t81" reading_order_no="78" segment_no="4" tag_type="text">) will be assigned for that patient.</text>
<text top="298" left="313" width="52" height="10" font="font9" id="p1_t82" reading_order_no="79" segment_no="7" tag_type="title"><b>Discussion</b></text>
<text top="310" left="313" width="241" height="9" font="font4" id="p1_t83" reading_order_no="80" segment_no="8" tag_type="text">The CASCADE study is a novel randomized double-blind</text>
<text top="322" left="313" width="241" height="9" font="font4" id="p1_t84" reading_order_no="81" segment_no="8" tag_type="text">placebo-controlled trial that will help clarify the contro-</text>
<text top="333" left="313" width="241" height="9" font="font4" id="p1_t85" reading_order_no="82" segment_no="8" tag_type="text">versial issue of antiplatelet therapy following CABG sur-</text>
<text top="345" left="313" width="241" height="9" font="font4" id="p1_t86" reading_order_no="83" segment_no="8" tag_type="text">gery. Specifically, it will answer the questions of whether</text>
<text top="357" left="313" width="241" height="9" font="font4" id="p1_t87" reading_order_no="84" segment_no="8" tag_type="text">the addition of clopidogrel to aspirin is safe following car-</text>
<text top="369" left="313" width="241" height="9" font="font4" id="p1_t88" reading_order_no="85" segment_no="8" tag_type="text">diac surgery and whether it reduces saphenous vein graft</text>
<text top="380" left="313" width="241" height="9" font="font4" id="p1_t89" reading_order_no="86" segment_no="8" tag_type="text">intimal hyperplasia. Although subgroup analyses of previ-</text>
<text top="392" left="313" width="241" height="9" font="font4" id="p1_t90" reading_order_no="87" segment_no="8" tag_type="text">ous trials have suggested a benefit of clopidogrel in car-</text>
<text top="404" left="313" width="241" height="9" font="font4" id="p1_t91" reading_order_no="88" segment_no="8" tag_type="text">diac surgery patients [<a href="">39,42,43</a>], no trial to date has</text>
<text top="416" left="313" width="241" height="9" font="font4" id="p1_t92" reading_order_no="89" segment_no="8" tag_type="text">specifically focused on the clinical or angiographic out-</text>
<text top="427" left="313" width="241" height="9" font="font4" id="p1_t93" reading_order_no="90" segment_no="8" tag_type="text">comes in patients treated with clopidogrel therapy imme-</text>
<text top="439" left="313" width="241" height="9" font="font4" id="p1_t94" reading_order_no="91" segment_no="8" tag_type="text">diately after surgical revascularization. Should the</text>
<text top="451" left="313" width="241" height="9" font="font4" id="p1_t95" reading_order_no="92" segment_no="8" tag_type="text">combination of clopidogrel and aspirin reduce the proc-</text>
<text top="463" left="313" width="241" height="9" font="font4" id="p1_t96" reading_order_no="93" segment_no="8" tag_type="text">ess of vein graft intimal hyperplasia, the CASCADE trial</text>
<text top="474" left="313" width="241" height="9" font="font4" id="p1_t97" reading_order_no="94" segment_no="8" tag_type="text">has the potential to redefine modern antiplatelet manage-</text>
<text top="486" left="313" width="168" height="9" font="font4" id="p1_t98" reading_order_no="95" segment_no="8" tag_type="text">ment of coronary artery bypass patients.</text>
<text top="510" left="313" width="241" height="9" font="font4" id="p1_t99" reading_order_no="96" segment_no="13" tag_type="text">We believe that the strengths of this study are its rand-</text>
<text top="521" left="313" width="241" height="9" font="font4" id="p1_t100" reading_order_no="97" segment_no="13" tag_type="text">omized and blinded design. Patients will be randomized</text>
<text top="533" left="313" width="241" height="9" font="font4" id="p1_t101" reading_order_no="98" segment_no="13" tag_type="text">into two treatment groups, and graft selection for IVUS</text>
<text top="545" left="313" width="241" height="9" font="font4" id="p1_t102" reading_order_no="99" segment_no="13" tag_type="text">imaging will be randomized within each patient. Blinding</text>
<text top="557" left="313" width="241" height="9" font="font4" id="p1_t103" reading_order_no="100" segment_no="13" tag_type="text">will occur for all patients and health care providers, and</text>
<text top="568" left="313" width="241" height="9" font="font4" id="p1_t104" reading_order_no="101" segment_no="13" tag_type="text">the IVUS and angiogram images will be interpreted by an</text>
<text top="580" left="313" width="241" height="9" font="font4" id="p1_t105" reading_order_no="102" segment_no="13" tag_type="text">external blinded core laboratory. While the process of inti-</text>
<text top="592" left="313" width="241" height="9" font="font4" id="p1_t106" reading_order_no="103" segment_no="13" tag_type="text">mal hyperplasia may be reduced in the trial, the study will</text>
<text top="604" left="313" width="241" height="9" font="font4" id="p1_t107" reading_order_no="104" segment_no="13" tag_type="text">not be powered to demonstrate a difference in</text>
<text top="615" left="313" width="241" height="9" font="font4" id="p1_t108" reading_order_no="105" segment_no="13" tag_type="text">angiographic patency or freedom from coronary events</text>
<text top="627" left="313" width="241" height="9" font="font4" id="p1_t109" reading_order_no="106" segment_no="13" tag_type="text">following CABG. In order to demonstrate a difference in</text>
<text top="639" left="313" width="241" height="9" font="font4" id="p1_t110" reading_order_no="107" segment_no="13" tag_type="text">either of these outcomes, a considerably larger sample size</text>
<text top="651" left="313" width="202" height="9" font="font4" id="p1_t111" reading_order_no="108" segment_no="13" tag_type="text">and longer follow-up period would be required.</text>
<text top="674" left="313" width="241" height="9" font="font4" id="p1_t112" reading_order_no="109" segment_no="16" tag_type="text">The results of this randomized trial will be generalizable</text>
<text top="686" left="313" width="241" height="9" font="font4" id="p1_t113" reading_order_no="110" segment_no="16" tag_type="text">to all patients undergoing standard CABG or OPCAB sur-</text>
<text top="698" left="313" width="241" height="9" font="font4" id="p1_t114" reading_order_no="111" segment_no="16" tag_type="text">gery with saphenous vein. Although the trial enrolment is</text>
<text top="709" left="313" width="241" height="9" font="font4" id="p1_t115" reading_order_no="112" segment_no="16" tag_type="text">limited to lower risk patients, it is anticipated that the</text>
<text top="721" left="313" width="241" height="9" font="font4" id="p1_t116" reading_order_no="113" segment_no="16" tag_type="text">results will also be applicable to higher risk patients with</text>
</page>
</pdf2xml>
